Navigation Links
Cardio Vascular Medical Device Announces Forward Stock Split
Date:12/2/2009

HAIFA, Isreal, December 2 /PRNewswire-FirstCall/ -- Cardio Vascular Medical Device Corp. (CVSL.OB), a leading developer of advanced cardiovascular surgery technology, today announced that the company's Board of Directors approved a one-for-three forward stock split, in the form of a stock dividend, payable to Cardio Vascular Medical Device shareholders.

The Company will announce in due course the estimated date the stock split will be payable and the related record date of the shareholders. The stock split is subject to FINRA approval. When the forward stock split becomes effective, shareholders of common stock will receive an additional two shares for each share held at the record date.

"We are pleased to announce this forward stock split for our shareholders," stated Eli Gonen, CEO of Cardio Vascular Medical Device Corp. "We expect that the Board's decision will improve liquidity and trading volume in our company's stock."

About Cardio Vascular Medical Device

Cardio Vascular Medical Device holds a US patent for an innovative next-generation "steerable guidewire" applicable for all angioplasty (PCTA) procedures. The technology hinges on a bendable tip that improves guidewire performance, enables faster procedure completion, and provides cost benefits for patients as well as healthcare providers. The guidewire has a unique opportunity to become the guidewire of choice for surgeons throughout the world.

Learn more about Cardio Vascular Medical Device at: http://www.cvslmedical.com

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Cardio Vascular Medical Device Corp. and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated in the forward-looking statements. Cardio Vascular Medical Device Corp. public filings may be viewed at http://www.sec.gov.


    Contact:

    Alex Traiman
    Media Relations
    +1-646-863-9729

    Asher Zwebner
    +972-54-464-6363
    asher@fxmng.com


SOURCE Cardio Vascular Medical Device Corp.


'/>"/>
SOURCE Cardio Vascular Medical Device Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Zargis Cardioscan(TM) Featured on The Early Show on CBS
2. CardioGenics Provides Update on Agreement with Merck Chimie for Its Silver Coated Paramagnetic Beads
3. MAQUET Cardiovascular Receives Guaranteed Two-Year Sole Source Contract From Novation for Beating Heart Surgical Devices
4. Reportlinker Adds Cardiovascular Catheters and Systems - Global Market Opportunities
5. Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference
6. CardioGenics Holdings Inc. Featured in Medical Device Daily
7. eCardio Named One of Houstons Fastest Growing Technology Companies at the 2009 Houston Business Journal FastTech 50 Awards Luncheon
8. Cardio Vascular Medical Device Launches Corporate Website
9. Cardiogenesis Reports Third Quarter 2009 Results
10. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
11. ATS Medical to Participate in the 2009 Canaccord Adams Cardiovascular Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... REDWOOD CITY, Calif., Feb. 23, 2017 Nevro Corp. ... innovative evidence-based solutions for the treatment of chronic pain, today ... ended December 31, 2016. 2016 Accomplishment & ... the full year 2016, an increase of 228% as reported, ... million for 2016, an increase of 612% over the prior ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology:
(Date:2/26/2017)... ... 26, 2017 , ... IndustryArchive.Org . is announcing a new way for ... will now only pay for B.A.N.T. quality sales leads based on the Sellers decision ... the new reality that B2B buyers are controlling the sales process via the Internet ...
(Date:2/26/2017)... , ... February 26, 2017 , ... ... disease (PD) in persons with a specific LRRK2 mutation, according to a study ... Previous studies have provided evidence of a link between pesticides and incidence of ...
(Date:2/24/2017)... ... February 24, 2017 , ... Only two months after the official ... (ILTM) show in Cannes (France), XO Private has initiated a second print-run of its ... measures almost a metre across when open, weighs in at more than six kilos, ...
(Date:2/24/2017)... ... 24, 2017 , ... The Smart Machine Age is here, and it’s disrupting ... percent of all jobs in the United States may be taken over by technology ... the aggressive know-it-all who steamrolls over colleagues is drawing to a close. Success will ...
(Date:2/24/2017)... Australia (PRWEB) , ... February 24, 2017 , ... The ... AU) offers Erik Schanssema ’s true account of his paramedic experiences. Schanssema describes ... stress disorder and his attempts to overcome them. , Schanssema, initially unsure of ...
Breaking Medicine News(10 mins):